Position Your Company at the Heart of a $19B Amylin Opportunity
As amylin rapidly emerges as a major next-generation obesity opportunity, biopharma teams are running into practical development bottlenecks that external partners are uniquely positioned to solve.
Across our industry research, developers highlighted limited access to amylin-specific assays, antibodies, screening platforms and ready-to-use preclinical models, alongside uncertainty around species translation and receptor biology.
Clinical teams are also looking for CRO partners with obesity expertise, efficient recruitment networks and the ability to generate robust, decision-enabling data. Imaging and biomarker specialists are becoming increasingly important as developers seek to differentiate therapies beyond headline weight loss by measuring lean mass preservation, adipose distribution, organ effects and broader cardiometabolic outcomes.
The Amylin-Based Therapeutics Summit brings these needs directly into the room. By partnering, your company can:
- Showcase solutions against clearly identified amylin development bottlenecks
- Educate biopharma teams on capabilities they may not yet know are available
- Build relationships with companies actively progressing amylin programs
- Position their technologies as critical enablers of faster, more confident development decisions
Our Audience Want to Meet:
- Developers have highlighted limited access to amylin-specific assays, antibodies, screening platforms and ready-to-use preclinical models, alongside uncertainty around species translation and receptor biology.
- Clinical teams are also looking for CRO partners with obesity expertise, efficient recruitment networks and the ability to generate robust, decision-enabling data.
- Imaging and biomarker specialists are becoming increasingly important as developers seek to differentiate therapies beyond headline weight loss by measuring lean mass preservation, adipose distribution, organ effects and broader cardiometabolic outcomes.
What to Expect?
Expand Beyond the GLP-1 Network
Connect with a new and fast-growing group of biotech and pharma teams exploring amylin across obesity, diabetes and other emerging indications, helping you extend relationships beyond the established GLP-1 ecosystem.
Meet Amylin Drug Developers
Build face-to-face relationships with teams actively advancing amylin programs and seeking external expertise across preclinical, translational and clinical development.
Demonstrate Your Amylin Expertise
Showcase how your models, biomarkers, imaging technologies or clinical capabilities can help solve amylin-specific development challenges through speaking, panels and exhibition opportunities.
Position Your Brand Across an Indication-Agnostic Community
Gain visibility with decision-makers working across the full therapeutic potential of amylin, rather than a single disease area, creating opportunities to support programs across multiple indications.
Gain Market Intelligence
Hear directly from leading developers and KOLs on emerging scientific priorities, translational bottlenecks, clinical strategies and where demand for external solutions is growing.
Key Interest Areas
Our attendees from biotech and pharma are looking for service and solution providers with capabilities in the below areas but not limited to:
Preclinical CROs
Preclinical Rat Models
Imaging
Biomarkers
Clinical CROs
Hear What Previous Obesity Events Series Partners Have to Say:
I always enjoy the speed networking and there more C-level decision makers at this conference which is very good
Chief Globalization Officer, AMRA Medical
Great to have big pharma there in such a personal meeting
Imaging Director, Antaros Medical
Good scientific content, network session
Founder & Chief Strategy Officer, Ovation.io
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include
Available Inventory
We have a range of inventory from standard booth and speaking slots to more bespoke deliverable such as badges, exclusive dinners and tours to help elevate your brand.
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Connor Drake
Partnerships Director
Amylin-Based Therapeutics Summit
Maintain Your Competitive Edge
Position your company alongside leading solution providers supporting the next generation of amylin therapeutics, and keep your brand front of mind as biopharma teams look beyond GLP-1s for new development partners.
Network With Amylin Decision-Makers
Connect directly with senior scientific and strategic leaders advancing amylin programs across an indication-agnostic audience, spanning obesity, diabetes and emerging therapeutic opportunities.
Showcase Your Capabilities
Highlight how your technologies and services can solve amylin-specific challenges through tailored sponsorship opportunities across branding, presenting and exhibiting.